News
KOD
3.380
+1.50%
0.050
Weekly Report: what happened at KOD last week (0415-0419)?
Weekly Report · 2d ago
BGC, DRS and AMTX are among after hour movers
Seeking Alpha · 5d ago
Weekly Report: what happened at KOD last week (0408-0412)?
Weekly Report · 04/15 11:37
Weekly Report: what happened at KOD last week (0401-0405)?
Weekly Report · 04/08 11:43
Kodiak Sciences Is Maintained at Neutral by UBS
Dow Jones · 04/04 15:28
Kodiak Sciences Price Target Raised to $5.00/Share From $3.00 by UBS
Dow Jones · 04/04 15:28
UBS Maintains Neutral on Kodiak Sciences, Raises Price Target to $5
Benzinga · 04/04 15:17
KODIAK SCIENCES INC <KOD.O>: UBS RAISES TARGET PRICE TO $5 FROM $3
Reuters · 04/04 14:46
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Aesthetic Medical Intl (NASDAQ:AIH) shares rose 14.0% to $0.52 during Wednesday's after-market session. Kineta shares rose 8.46% and Simulations Plus shares increased by 6.74%. The company's market cap stands at $24.9 million.
Benzinga · 04/03 20:31
Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus
NASDAQ · 04/01 16:00
Kodiak Sciences Is Maintained at Underweight by Barclays
Dow Jones · 04/01 13:26
Kodiak Sciences Price Target Raised to $3.00/Share From $2.00 by Barclays
Dow Jones · 04/01 13:26
Barclays Maintains Underweight on Kodiak Sciences, Raises Price Target to $3
Benzinga · 04/01 13:15
Take the Zacks Approach to Beat the Market: NVIDIA, Dell, Modine in Focus
NASDAQ · 04/01 12:03
Weekly Report: what happened at KOD last week (0325-0329)?
Weekly Report · 04/01 11:39
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), Walgreens Boots Alliance (WBA) and Kodiak Sciences (KOD)
Analysts have new ratings on OptimizeRx, Walgreens Boots Alliance and Kodiak Sciences. Barclays analyst Stephanie Davis maintained a Hold rating on optimizerx today and set a price target of $15.00. The company's shares closed at $12.15 today. Walgreen's Boots Alliance has a Sell rating.
TipRanks · 04/01 07:40
KODIAK SCIENCES INC <KOD.O>: JEFFERIES RAISES TARGET PRICE TO $7 FROM $3.5
Reuters · 04/01 03:55
Barclays Sticks to Their Sell Rating for Kodiak Sciences (KOD)
TipRanks · 03/30 01:25
12 Health Care Stocks Moving In Friday's Intraday Session
Avalo Therapeutics (NASDAQ:AVTX) shares increased by 364.8% to $22.08 during Friday's regular session. The company's market cap stands at $510.4 million. Nexalin Technology shares moved upwards by 83.33% and Biodexa Pharmaceuticals stock increased by 81.6%. Losers include Tonix Pharmaceuticals and Kodiak Sciences.
Benzinga · 03/29 16:30
Kodiak Sciences Inc reports results for the quarter ended in December - Earnings Summary
Kodiak Sciences Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of $1.13 per share. The mean expectation of six analysts was for a loss of 77 cents. Kodiak Sciences shares had risen by 145.1% this quarter.
Reuters · 03/28 21:02
More
Webull provides a variety of real-time KOD stock news. You can receive the latest news about Kodiak Sciences Inc. through multiple platforms. This information may help you make smarter investment decisions.
About KOD
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.